Physician profile
Manoj Jain
NPI 1285620369
$6,667.21
in general payments reported to CMS, 2019-2025
57 companies · $552 in 2025
The $552 reported for 2025 was more than what 76% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $155 · 2021: $170 · 2022: $1,099 · 2023: $1,773 · 2024: $2,228 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,553.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $640.60 | 2019-2025 | Kisqali, Piqray |
| Astrazeneca Pharmaceuticals LP | $594.36 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Janssen Biotech, INC. | $539.95 | 2019-2024 | Erleada, Akeega, Imbruvica |
| Daiichi Sankyo INC. | $492.50 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Amgen INC. | $274.16 | 2020-2023 | Nplate, Xgeva, Vectibix |
| Bayer Healthcare Pharmaceuticals INC. | $269.96 | 2019-2024 | |
| Pfizer INC. | $236.17 | 2023-2025 | |
| Seagen INC. | $207.07 | 2020-2023 | Padcev, Tivdak, Tukysa |
| Lilly USA, LLC | $200.51 | 2020-2024 | Jaypirca, Retevmo, Verzenio |
| Merck Sharp & Dohme LLC | $181.71 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Puma Biotechnology, INC. | $175.38 | 2022-2025 | |
| Genzyme Corporation | $144.60 | 2021-2024 | |
| Exelixis INC. | $136.89 | 2022-2025 | Cabometyx |
| Astellas Pharma US INC | $136.05 | 2023-2024 | Padcev, Vyloy, Xospata |
| Gilead Sciences, INC. | $134.42 | 2022-2025 | Trodelvy |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $126.08 | 2022-2024 | |
| Taiho Oncology, INC. | $125.22 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $123.56 | 2020-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $120.56 | 2023-2025 | |
| Genentech USA, INC. | $116.32 | 2020-2024 | Tecentriq, Alecensa, Columvi |
| Glaxosmithkline, LLC. | $107.73 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Progenics Pharmaceuticals, INC. | $100.00 | 2022 | |
| Kyowa Kirin, INC. | $99.19 | 2023-2024 | Poteligeo |
| Aveo Pharmaceuticals, INC. | $97.10 | 2022-2023 | Fotivda |
| Eisai INC. | $83.06 | 2020-2024 | |
| Myriad Genetic Laboratories, INC. | $78.68 | 2022-2023 | Precisetumor |
| Incyte Corporation | $72.41 | 2019-2024 | Monjuvi, Pemazyre, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $71.72 | 2019-2023 | |
| Organon LLC | $66.08 | 2022-2023 | Ontruzant, Renflexis |
| Morphosys, US INC. | $62.29 | 2022-2023 | Monjuvi |
| Pharming Healthcare, INC. | $61.90 | 2023-2024 | Ruconest |
| Sobi, INC | $59.08 | 2022-2024 | |
| Novo Nordisk INC | $48.87 | 2024 | Rybelsus, Ozempic |
| Celgene Corporation | $46.59 | 2024 | Opdualag |
| Array Biopharma INC | $44.92 | 2024 | Braftovi, Mektovi, Tukysa |
| Adaptive Biotechnologies Corporation | $43.72 | 2022-2025 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.85 | 2019-2025 | |
| Adc Therapeutics America, INC. | $40.97 | 2024-2025 | |
| Coherus Oncology, INC. | $38.75 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.59 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $30.39 | 2019-2020 | |
| Foundation Medicine, INC. | $29.15 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $28.90 | 2019 | |
| Fresenius Kabi USA, LLC | $28.23 | 2024 | Stimufend |
| Stemline Therapeutics INC. | $28.16 | 2024 | Orserdu |
| Mirati Therapeutics, INC. | $25.94 | 2023 | Krazati |
| Alexion Pharmaceuticals, INC. | $25.74 | 2021-2024 | Ultomiris |
| Sumitomo Pharma America, INC. | $24.38 | 2023 | Orgovyx |
| Tersera Therapeutics LLC | $22.43 | 2024 | Xermelo |
| Epizyme, INC. | $20.55 | 2022 | |
| Blueprint Medicines Corporation | $20.12 | 2021 | |
| Servier Pharmaceuticals LLC | $19.40 | 2023 | |
| Tesaro, INC. | $19.23 | 2019 | |
| Rigel Pharmaceuticals, INC. | $17.71 | 2023 | Rezlidhia, Tavalisse |
| Secura Bio, INC. | $16.97 | 2019 | |
| Shire North American Group INC | $14.85 | 2019 | |
| Recordati_rare_diseases_inc. | $14.49 | 2023 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.